Pre-market hot trades in US stocks: Opendoor Tech Series A - CW26 up 13.56% in pre-market; Ohmyhome up 3.23% in pre-market

Popular Pre-Market Trades in US Stocks Opendoor Tech Series A - CW26, up 13.56% in pre-market, with no significant news recently. Trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Ohmyhome, up 3.23% in pre-market, with no significant news recently. Trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Top Gainers in Pre-Market US Stocks AlphaTON Capital, up 141.76% in pre-market, with no significant news recently. Trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Ambitions Enterprise, up 141.10% in pre-market, with no significant news recently. Trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Decoy Therapeutics is up 85.28% in pre-market. Based on recent news, On January 13, Decoy Therapeutics announced an agreement with the Gates Foundation to develop a platform for manufacturing antiviral drugs. This platform aims to make antiviral drugs widely available in low- and middle-income countries. This news drove the stock price up. On January 13, the company plans to validate its experimental nasal spray for preventing coronavirus infections in immunocompromised populations and expects to submit applications for its main antiviral candidates to US regulators within a year. This move has boosted market confidence. On January 13, the company received funding support from the Gates Foundation to utilize its platform for manufacturing antiviral drugs and promoting them in low- and middle-income countries. This news further boosted the stock price. The antiviral drug development sector has been active recently, with significant capital inflow